Cargando…
Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis
BACKGROUND: This meta-analysis was performed to assess the efficacy of risedronate in increasing bone mineral density (BMD) in patients undergoing primary total hip arthroplasty (THA). METHODS: We systematically searched the following databases: PubMed, Embase, Web of Science, Cochrane Library, and...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992663/ https://www.ncbi.nlm.nih.gov/pubmed/29880021 http://dx.doi.org/10.1186/s13018-018-0794-1 |
_version_ | 1783330069785083904 |
---|---|
author | Li, Qifeng Xu, Baoshan |
author_facet | Li, Qifeng Xu, Baoshan |
author_sort | Li, Qifeng |
collection | PubMed |
description | BACKGROUND: This meta-analysis was performed to assess the efficacy of risedronate in increasing bone mineral density (BMD) in patients undergoing primary total hip arthroplasty (THA). METHODS: We systematically searched the following databases: PubMed, Embase, Web of Science, Cochrane Library, and Chinese Wanfang database from inception up to October 2017. Included patients were prepared for THA and were separated into two groups: intervention group (risedronate treatment) and control group (placebo treatment). BMD change in Gruen zone 1 and 7 were primary outcomes. Meta-analysis was performed using Stata 12.0 software. RESULTS: Five randomized controlled trials (RCTs) involving 259 patients (risedronate group = 127, control group = 132) were finally included in this meta-analysis. Meta-analysis indicated that oral risedronate significantly increased the BMD change in Gruen zone 1. However, there was little clinical significance between the risedronate and control group in terms of the Gruen zones 2, 3, and 7. Oral risedronate significantly increased the Harris hip scores compared with the control group (P < 0.05). CONCLUSION: Oral risedronate could significantly reduce peri-prosthetic bone resorption around an uncemented femoral stem (Gruen zone 1) after THA. Due to the limited included studies, more high-quality randomized controlled trials (RCTs) were still needed to identify the efficacy of risedronate for bone loss in THA. |
format | Online Article Text |
id | pubmed-5992663 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59926632018-06-21 Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis Li, Qifeng Xu, Baoshan J Orthop Surg Res Review Article BACKGROUND: This meta-analysis was performed to assess the efficacy of risedronate in increasing bone mineral density (BMD) in patients undergoing primary total hip arthroplasty (THA). METHODS: We systematically searched the following databases: PubMed, Embase, Web of Science, Cochrane Library, and Chinese Wanfang database from inception up to October 2017. Included patients were prepared for THA and were separated into two groups: intervention group (risedronate treatment) and control group (placebo treatment). BMD change in Gruen zone 1 and 7 were primary outcomes. Meta-analysis was performed using Stata 12.0 software. RESULTS: Five randomized controlled trials (RCTs) involving 259 patients (risedronate group = 127, control group = 132) were finally included in this meta-analysis. Meta-analysis indicated that oral risedronate significantly increased the BMD change in Gruen zone 1. However, there was little clinical significance between the risedronate and control group in terms of the Gruen zones 2, 3, and 7. Oral risedronate significantly increased the Harris hip scores compared with the control group (P < 0.05). CONCLUSION: Oral risedronate could significantly reduce peri-prosthetic bone resorption around an uncemented femoral stem (Gruen zone 1) after THA. Due to the limited included studies, more high-quality randomized controlled trials (RCTs) were still needed to identify the efficacy of risedronate for bone loss in THA. BioMed Central 2018-06-07 /pmc/articles/PMC5992663/ /pubmed/29880021 http://dx.doi.org/10.1186/s13018-018-0794-1 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Article Li, Qifeng Xu, Baoshan Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis |
title | Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis |
title_full | Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis |
title_fullStr | Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis |
title_full_unstemmed | Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis |
title_short | Oral risedronate increases Gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis |
title_sort | oral risedronate increases gruen zone bone mineral density after primary total hip arthroplasty: a meta-analysis |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992663/ https://www.ncbi.nlm.nih.gov/pubmed/29880021 http://dx.doi.org/10.1186/s13018-018-0794-1 |
work_keys_str_mv | AT liqifeng oralrisedronateincreasesgruenzonebonemineraldensityafterprimarytotalhiparthroplastyametaanalysis AT xubaoshan oralrisedronateincreasesgruenzonebonemineraldensityafterprimarytotalhiparthroplastyametaanalysis |